Low T Or High Risk? Testosterone Treatments And Heart Attacks

Jan 29 2014, 10:52pm CST | by

Maybe ‘Low T’ is something men may want to live with, after all. A new study finds that treatments for boosting low testosterone levels – which pervasive marketing warns can interfere with sex drive, moods and energy – may increase the risk of heart attacks in large swathes of men.

Specifically, the risk doubled during the first three months after starting therapy in men younger than 65 years old who had a history of heart disease. Similarly, the risk also doubled for all men older than 65 – those with or without heart disease – shortly after beginning treatment, according the study published in PLOS One.

At first blush, this may not seem to be heart-stopping news. Previous studies have suggested such therapies – including the widely touted AndroGel that is sold by AbbVie – can increase cardiovascular risk. In fact, a small study published in The New England Journal of Medicine three years ago reached such a conclusion (read this).

But the latest study is different and, consequently, may have the potential to change the conversation about the extent to which using testosterone treatments is desirable. And the results are prompting calls for the FDA to update product labeling (see this, this and this) in order to flag cardiovascular concerns.

Why? Unlike earlier efforts, the latest study examined a large population. The researchers culled records of 55,593 men who had been prescribed testosterone treatments, including 48,539 who were younger than 65 years old. The data was obtained from Truven Health Analytics, which aggregates patient records.

“Due to the size of our study, we were able to examine heart attacks, as opposed to a variety of cardiovascular conditions, and we were able to examine excess risk in the short term,” says William Finkle, the lead author and an epidemiologist at Consolidated Research, a statistics and software development firm. “Our study is also the first to include a substantial number of men under 65″ (here is the study).

An AbbVie spokesman did not respond to a request for comment.

The researchers also compared patients given testosterone treatments – which include the Axiron solution sold by Eli Lilly and the Androderm patch marketed by Actavis – with those given the Viagra and Cialis erectile dysfunction pills, since these are similarly prescribed for enhancing sexual performance.

Here, they found that men younger than 65 who were given testosterone boosters and had a history of heart disease were twice as likely to suffer a heart attack, relative to the impotence pills. The implication is that the increase in cardiovascular risk is due to the treatments, not the sexual behavior.

The findings come amid years of aggressive promotion of testosterone treatments. A study published last fall in the Journal of the American Medical Association noted that annual prescriptions for these elixirs rose more than five-fold from 2000 to 2011, reaching 5.3 million prescriptions. Sales totaled nearly $2 billion in 2012, according to IMS Health, the research firm.

The marketing has sometimes been controversial. Four years ago, a study in The New England Journal of Medicine found only 2 percent of men aged 40 to 80 suffered from ‘Low T,’ which is sometimes called male menopause, but the web site run by Abbott Laboratories (and now by AbbVie) was criticized for overstating the case.

And two years ago, a group of physicians and academics complained to the independent Pharmaceutical Advertising Advisory Board in Canada that an AndroGel campaign harmed public health by promoting unapproved uses and implying exaggerated effectiveness.

Consequently, the PLOS authors recommend further studies that can “assess the range of benefits and risks.” Although Sid Wolfe of Public Citizen Health Research Group believes the FDA should not wait to update the product labeling to reflect the risk of heart attacks.

“This study adds an enormous amount to what is known about the risks,” he argues. “It’s an important breakthrough and the implications are sobering, but unfortunately, there is nothing in the current labeling or the med guides for patients.”

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Department of Energy Program Administered Through the Electric Power Research Institute to Apply Over 120 Odyne Plug-In Hybrid Systems to Trucks Throughout North America
 
 
Cleared Of Fraud Against SMEs, RBS Eases Rules For Distressed Businesses
Last week, The Royal Bank of Scotland Group was cleared by law firm Clifford Chance over allegations that the U.K.-based banking group deliberately put failing small and medium enterprise customers out of business to...
 
 
Cost Savings Are Allowing Colgate To Invest Back In Building Brands And Products
In the past several quarters, balancing the business mix between developed and emerging markets has helped Colgate-Palmolive to achieve above market growth and experience only a moderate impact on net sales from...
 
 
Shift In Agricultural Sales Timing, Lower Chemical Prices Weigh On DuPont's Earnings Growth
DuPont reported modest earnings growth for the first quarter due to lower agricultural sales volume and continuing pricing pressures in the chemicals segment. The company’s adjusted diluted earnings per share of $1.58...
 
 
 

Latest from the Network

Apple's Sales Figures Prove A Sad Fact: There's Still No PC As Desirable As A Mac
Mac sales make up just a tenth of Apple's revenue, but they’ve received a significant amount of attention following the company’s quarterly report yesterday, both from analysts and from the CEO Tim Cook himself. Cook’s...
Read more on Apple Balla
 
Apple's Analysts Almost Universally Positive On The March Quarter Results
Apple’s shares are up over $40 today driven by its very solid March quarter results and better than expected guidance for the June quarter. I have summarized over a dozen sell-side notes below and many analysts have...
Read more on Apple Balla
 
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Waukesha, WI, April 24, 2014 --(PR.com)-- Odyne Systems of Waukesha and Inland Power Group of Butler, Wisconsin have teamed up to deliver on a $45.4 million contract from the Department of Energy, administered through...
Read more on Politics Balla
 
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Waukesha, WI, April 24, 2014 --(PR.com)-- Odyne Systems of Waukesha and Inland Power Group of Butler, Wisconsin have teamed up to deliver on a $45.4 million contract from the Department of Energy, administered through...
Read more on Business Balla
 
Cleared Of Fraud Against SMEs, RBS Eases Rules For Distressed Businesses
Last week, The Royal Bank of Scotland Group was cleared by law firm Clifford Chance over allegations that the U.K.-based banking group deliberately put failing small and medium enterprise customers out of business to...
Read more on Business Balla
 
Cost Savings Are Allowing Colgate To Invest Back In Building Brands And Products
In the past several quarters, balancing the business mix between developed and emerging markets has helped Colgate-Palmolive to achieve above market growth and experience only a moderate impact on net sales from...
Read more on Business Balla
 
Shift In Agricultural Sales Timing, Lower Chemical Prices Weigh On DuPont's Earnings Growth
DuPont reported modest earnings growth for the first quarter due to lower agricultural sales volume and continuing pricing pressures in the chemicals segment. The company’s adjusted diluted earnings per share of $1.58...
Read more on Business Balla
 
Google's Glass Explorer Program Was A Social Experiment That Backfired
Google Glass was launched without any clear explanation of what it was supposed to be used for. When promotional videos started to show people going about their daily routine, it quickly became clear that what we were...
Read more on Business Balla
 
America's 100 Best Corporate Citizens in 2014
America’s 10 Best Corporate Citizens In 2014 In December Bristol-Myers Squibb joined the Medicines Patent Pool, an international organization in Geneva, Switzerland, that makes drugs available at low cost to people...
Read more on Business Balla
 
Talent Knows No Limits
Last month I had the pleasure of attending Cirque Du Soleil’s Michael Jackson tribute The Immortal World Tour. To say the performance was out of this world would be an understatement. If you’ve ever seen a Cirque show...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla